TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278
Clinical trial NCT01031589 · COMPLETED
Trial details
- NCT number
- NCT01031589
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2010-01-01
- Primary completion
- 2011-07-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.